Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Century Therapeutics (IPSC) Non-Current Debt (2022)

Century Therapeutics (IPSC) has disclosed Non-Current Debt for 1 consecutive years, with $3.7 million as the latest value for Q4 2022.

  • Quarterly Non-Current Debt changed N/A to $3.7 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $3.7 million through Dec 2022, changed N/A year-over-year, with the annual reading at $3.7 million for FY2022, N/A changed from the prior year.
  • Non-Current Debt for Q4 2022 was $3.7 million at Century Therapeutics, down from $6.1 million in the prior quarter.
  • The five-year high for Non-Current Debt was $10.0 million in Q1 2022, with the low at $3.7 million in Q4 2022.